Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vanda Pharmaceuticals (VNDA) Consolidated Net Income (2016 - 2025)

Historic Consolidated Net Income for Vanda Pharmaceuticals (VNDA) over the last 17 years, with Q4 2025 value amounting to -$141.2 million.

  • Vanda Pharmaceuticals' Consolidated Net Income fell 277518.32% to -$141.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$220.5 million, marking a year-over-year decrease of 106663.14%. This contributed to the annual value of -$220.5 million for FY2025, which is 106652.91% down from last year.
  • Vanda Pharmaceuticals' Consolidated Net Income amounted to -$141.2 million in Q4 2025, which was down 277518.32% from -$22.6 million recorded in Q3 2025.
  • Vanda Pharmaceuticals' 5-year Consolidated Net Income high stood at $9.6 million for Q2 2021, and its period low was -$141.2 million during Q4 2025.
  • Over the past 5 years, Vanda Pharmaceuticals' median Consolidated Net Income value was -$1.1 million (recorded in 2023), while the average stood at -$9.9 million.
  • In the last 5 years, Vanda Pharmaceuticals' Consolidated Net Income surged by 185646.26% in 2021 and then crashed by 305777.78% in 2024.
  • Vanda Pharmaceuticals' Consolidated Net Income (Quarter) stood at $7.1 million in 2021, then fell by 2.96% to $6.9 million in 2022, then tumbled by 134.71% to -$2.4 million in 2023, then tumbled by 105.44% to -$4.9 million in 2024, then tumbled by 2775.18% to -$141.2 million in 2025.
  • Its Consolidated Net Income was -$141.2 million in Q4 2025, compared to -$22.6 million in Q3 2025 and -$27.2 million in Q2 2025.